The study would be more of the same with the emphasis on what the ongoing success/failure stats look like for a given product characteristic as shown by the assays done before treatment. If the stats did not hold up then the AA could be withdrawn.
They might add more data of curiosity, but we would not need to know about that.
- Forums
- ASX - By Stock
- MSB
- Ann: Remestemcel Clinical and Potency Studies Presented at Tandem
Ann: Remestemcel Clinical and Potency Studies Presented at Tandem, page-99
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B |
Open | High | Low | Value | Volume |
$1.15 | $1.17 | $1.13 | $3.743M | 3.261M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 78561 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 114667 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 78561 | 1.145 |
4 | 151270 | 1.140 |
4 | 53395 | 1.135 |
6 | 133073 | 1.130 |
3 | 101104 | 1.125 |
Price($) | Vol. | No. |
---|---|---|
1.160 | 114667 | 4 |
1.165 | 45573 | 3 |
1.170 | 67634 | 7 |
1.175 | 40867 | 3 |
1.180 | 27096 | 4 |
Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |